SCHEMBL873455

SCHEMBL873455

COC(=O)Cc1cnc(C)o1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.38
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
KDM4E B2RXH2 5/20 0.35
CCNE1 P24864 2/20 0.35
CDK2 P24941 2/20 0.35
GSK3B P49841 2/20 0.35
HSD17B10 Q99714 3/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 2/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
GLA P06280 1/20 0.35
FEN1 P39748 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12747076 0.84 SMN1; SMN2 (0.50) ALDH1A1KDM4ECCNE1CDK2GSK3B
SCHEMBL14146033 0.83 TSHR (0.39) ALDH1A1KDM4EHSD17B10HPGDFEN1
SCHEMBL15661443 0.81 HTT (0.40) HSP90AB1ALDH1A1NPC1RAB9ACYP4F2
SCHEMBL682873 0.79 HSD17B10 (0.41) ALDH1A1RAB9AKDM4ECCNE1CDK2
SCHEMBL17918751 0.79 CCNE1 (0.38) CCNE1CDK2GSK3BFEN1
SCHEMBL19179848 0.78 CCNE2 (0.41) HSP90AB1ALDH1A1NPC1RAB9ACYP4F2
SCHEMBL22723931 0.78 HTT (0.40) ALDH1A1RAB9ACCNE1CDK2GSK3B
SCHEMBL10150924 0.76 CCNE1 (0.41) CCNE1CDK2GSK3BHPGDFEN1
SCHEMBL12617050 0.74 HDAC1 (0.53) ALDH1A1NPC1RAB9AKDM4EHSD17B10
SCHEMBL18166990 0.73 CCNE2 (0.39) HSP90AB1ALDH1A1NPC1RAB9ACYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188075-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS THE BROAD INSTITUTE, INC. 2025-06-12 US disclosed
EP-4469457-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS The Broad Institute Inc. (US) 2024-12-04 EP disclosed
WO-2023147015-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS THE BROAD INSTITUTE, INC. (US) 2023-08-03 WO disclosed
EP-3564239-A1 ARYL HYDROCARBON RECEPTOR MODULATOR Shenzhen Immunova Pharmaceutical Co., Ltd. (CN) 2019-11-06 EP disclosed
US-9624200-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2017-04-18 US disclosed
US-20150087645-A1 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. 2015-03-26 US disclosed
US-8927546-B2 Therapeutic piperazines DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2015-01-06 US disclosed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP disclosed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO disclosed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087645-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D HSP90AB1 2564/4885ALDH1A1 1228/4885NPC1 1880/4885
US-20110065691-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D HSP90AB1 2564/4885ALDH1A1 1228/4885NPC1 1880/4885
US-20250188075-A1 SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS CSNK1A1, CSNK2A1, CSNK1A1L HSP90AB1 1962/4885ALDH1A1 1807/4885NPC1 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.